NR Times reports on the much-anticipated trial of ALS treatment AMX0035, in an interview with Machelle Manuel, head of global medical affairs at its creator Amylyx.

Recently approved for treating ALS in the US, AMX0035 is now the subject of a major phase 3 clinical trial taking place across the US and Europe. ALS is a relentlessly progressive and fatal neurodegenerative disorder that up until recent decades was thought to be impossible to treat. While the cause of the condition is still uncertain, a new wave of treatments is coming to the fore. Sign up to NR Times to read our interview in full.